New Launch9 Apr 2024, 10:25 pm
Lupin Limited Announces Launch of First Generic Version of Oracea® (Doxycycline Capsules) in the US, Estimated Sales of USD 128 Million
AI Summary
Lupin Limited, a global pharma major, announced the launch of the first generic version of Oracea® (Doxycycline Capsules, 40 mg) in the US after receiving approval from the US FDA. This product is indicated for the treatment of inflammatory lesions of rosacea in adult patients. The estimated annual sales in the US were USD 128 million (IQVIA MAT February 2024). Lupin is headquartered in Mumbai, India, and has a significant presence in various markets. The company is a leader in various pharmaceutical segments and invested 7.9% of its revenue in research and development in FY23. Lupin employs over 20,000 professionals worldwide and has been recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.
Key Highlights
- Lupin Limited announces launch of first generic version of Oracea® (Doxycycline Capsules, 40 mg) in the US
- Approval received from US FDA
- Product indicated for treatment of inflammatory lesions of rosacea in adult patients
- Estimated annual sales in the US were USD 128 million
- Lupin is a global pharma major with significant presence in various markets
- Company is a leader in various pharmaceutical segments and invested 7.9% of revenue in research and development in FY23
- Lupin employs over 20,000 professionals worldwide and has been recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.